Takeda Ventures senior investment director Ilan Zipkin has become the second high-profile departure from the unit in four months to join the Parker Institute for Cancer Immunotherapy.
Ilan Zipkin, senior investment director at Takeda Ventures, Japan-based pharmaceutical company Takeda’s corporate venturing unit, has left after five years to become vice-president of business development at the Parker Institute for Cancer Immunotherapy.
Parker Institute is a collaboration between US immunologists, cancer centres and universities including Memorial Sloan Kettering Cancer Center, Stanford Medicine, University of California, Los Angeles, University of California, San Francisco, University of Pennsylvania and University of Texas MD Anderson Cancer Center.
Zipkin’s departure from Takeda comes after 17…
